BiomX (NYSEAMERICAN:PHGE – Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.
BiomX Stock Down 20.0%
Shares of PHGE stock opened at $0.48 on Monday. BiomX has a 12-month low of $0.34 and a 12-month high of $1.94. The stock has a market capitalization of $12.44 million, a PE ratio of -0.56 and a beta of 1.42. The stock has a 50 day moving average of $0.45.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered their price target on shares of BiomX from $21.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 16th.
BiomX Company Profile
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
Featured Articles
- Five stocks we like better than BiomX
- Stock Sentiment Analysis: How it Works
- 3 Dividend Stocks Raising Payouts—and Backing It Up With Results
- How to trade penny stocks: A step-by-step guide
- 3 Stocks With Monopoly Power—and Minimal Competition
- Ride Out The Recession With These Dividend Kings
- Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact?
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
